AstraZeneca: Alexion Aims to Advance NMOSD Treatment Landscape with Exceptional ULTOMIRIS(R) Efficacy Data at ECTRIMS 2022
October 13, 2022
October 13, 2022
WILMINGTON, Delaware, Oct. 13 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022.
Data presented at the meeting will feature . . .
Alexion, AstraZeneca Rare Disease, will present new data showing significant advances for the treatment of anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, October 26 to 28, 2022.
Data presented at the meeting will feature . . .